Equipment sales weighted toward the second half and fourth quarter
First written in FY2016. 9 of 21 entries say "Worsened", first in FY2021-Q1. Latest entry: 2026-05-11.
Techno Medica moved to the "Worse" side of this theme in 2020, 2 years before the typical company in this theme (2022).
The whole theme swung hardest in 2020: 10 of 32 companies on the "Worse" side.
9 other companies' latest entry also says "Mitigated".
- 2026-05-11MitigatedEarnings
「In the domestic market, sales projects for equipment and systems planned for large-scale facilities progressed steadily, and net sales amounted to ¥4,446,008 thousand, up 37.3% year on year.」
Projects for large-scale facilities progressed steadily, driving an increase in domestic sales of blood collection tube preparation systems and related systems. - FY2026-H1WorsenedAnnual report
「In the domestic market, revenue was ¥895.467 million, down 8.3% year on year, because sales of equipment and systems for large-scale facilities were lower than in the same period of the previous year.」
Sales of equipment and systems for large-scale facilities were lower than in the same period of the previous year, and domestic revenue fell 8.3%. Performance fluctuations between periods associated with dependence on large-scale projects deteriorated in the interim results. - FY2025MaterialisedAnnual report
「In the domestic market, revenue was ¥3,237.325 million, down 21.9% from the previous fiscal year, because sales projects for equipment and systems for large-scale facilities were frequently brought forward or postponed.」
Projects for large-scale facilities were in fact brought forward or postponed, and domestic revenue from blood collection tube preparation equipment and systems fell 21.9%. The risk of performance fluctuations caused by project timing materialized in full-year results. - FY2025-H1MaterialisedAnnual report
「Revenue in the domestic market was ¥976.445 million, down 12.0% year on year, because some sales projects for equipment and systems for large-scale facilities had been brought forward into the previous fiscal year.」
The bringing forward of projects for large-scale facilities into the previous fiscal year caused domestic revenue from blood collection tube preparation equipment and systems for the current interim period to fall 12.0% year on year. The risk of sales fluctuations caused by project timing materialized in actual results. - FY2024RestatedAnnual report
「Sales of our core blood collection tube preparation equipment and systems business tend to be concentrated in the second half and fourth quarter because of the timing of orders from, and delivery requests by, medical institutions, which are the primary customers for these products.」
The disclosure continues to cover the concentration of equipment sales in the second half and fourth quarter and the risk that sales may be deferred to the following fiscal year because of delays in introducing higher-level systems. - FY2024-Q2MitigatedAnnual report
「Revenue in the domestic market was ¥1,110.188 million, up 17.1% year on year, due in part to the smooth progress of sales projects for large units in the second quarter.」
In contrast to the project timing shifts and insufficient number of projects seen in FY2024-Q1, sales projects for large units progressed smoothly in the second quarter, and domestic revenue increased 17.1% year on year. The risk of fluctuations caused by project timing eased during the quarter, but this does not indicate that the seasonality itself has been eliminated. - FY2024-Q1WorsenedAnnual report
「Although a certain number of projects was expected from the second quarter onward, the number of projects in both Japan and overseas was low in the first quarter. Domestic revenue was ¥388.332 million, down 7.0% year on year, while overseas revenue was ¥24.484 million, down 54.4% year on year, because sales projects for both small and large units shifted to the second quarter or later.」
The number of projects was low in both Japan and overseas in the first quarter, and overseas projects for small and large units shifted to the second quarter or later, causing the timing concentration and project-timing volatility of equipment sales to emerge in actual results. - FY2023WorsenedAnnual report
「Revenue in the domestic market was ¥3,292.328 million, down 6.5% from the previous fiscal year, due in part to a decline in large projects and the postponement of certain projects to the following fiscal year or later.」
The decline in large projects and postponement of sales to the following fiscal year or later caused domestic revenue from blood collection tube preparation equipment and systems to fall 6.5% from the previous fiscal year, with performance fluctuations caused by project timing also evident in full-year results. - FY2023-Q3WorsenedAnnual report
「Revenue from blood collection tube preparation equipment and systems for the cumulative third quarter amounted to ¥1,874.769 million, down 8.3% year on year. Revenue in the domestic market was ¥1,704.908 million, down 5.6% year on year, mainly because the number of large projects declined from the same period of the previous year.」
Domestic revenue from blood collection tube preparation equipment and systems fell 5.6% year on year because of the decline in large projects, and the risk of performance fluctuations caused by project size and timing deteriorated in actual results. - FY2023-Q2WorsenedAnnual report
「Revenue in the domestic market was ¥948.351 million, down 25.6% year on year, as the number of large projects declined despite an increase in medium-sized and small projects.」
While medium-sized and small projects increased, domestic revenue from blood collection tube preparation equipment and systems fell 25.6% year on year because of the decline in large projects, demonstrating in actual results the performance fluctuations caused by project size and timing. - FY2022RestatedAnnual report
「Sales of our core blood collection tube preparation equipment and systems business tend to be concentrated in the second half and fourth quarter because of the timing of orders from, and delivery requests by, medical institutions, which are the primary customers for these products.」
The disclosure continues to cover the concentration of equipment sales in the second half and fourth quarter and the risk that sales may be deferred to the following fiscal year because of delays in introducing higher-level systems. - FY2022-Q3MitigatedAnnual report
「Revenue from blood collection tube preparation equipment and systems for the cumulative third quarter amounted to ¥2,044.583 million, up 25.0% year on year. In the same period of the previous year, sales had declined as replacement demand for large-scale projects reached a trough, but sales recovered, and the number of units sold of small and medium-sized models increased substantially, among other factors, resulting in domestic revenue of ¥1,805.185 million, up 31.6% year on year.」
Domestic revenue from blood collection tube preparation equipment and systems recovered from the trough in replacement demand for large-scale projects in the same period of the previous year, increasing 31.6% year on year. Recent sales fluctuations caused by the timing concentration of projects eased, but this does not indicate that the seasonality itself has been eliminated. - FY2022-Q2MitigatedAnnual report
「As replacement demand for large-scale projects had been at a trough in the same period of the previous year, revenue in the domestic market was ¥1,274.853 million, up 57.3% year on year as a result of this rebound,」
As a result of the rebound from the trough in replacement demand for large-scale projects in the same period of the previous year, domestic revenue from blood collection tube preparation equipment and systems increased 57.3% year on year on a cumulative basis for the quarter. The recent sales fluctuations caused by the trough in replacement demand have eased, but this does not indicate that the seasonality or concentration in project timing itself has been eliminated. - FY2021WorsenedAnnual report
「Revenue in the domestic market was ¥3,005.125 million, down 21.4% from the previous fiscal year, as large-scale replacement projects had run their course by the previous fiscal year and replacement demand was at a trough,」
The completion of large-scale replacement projects and the trough in replacement demand were reflected in full-year results, with domestic revenue from blood collection tube preparation equipment and systems down 21.4% from the previous fiscal year. - FY2021-Q3WorsenedAnnual report
「Revenue in the domestic market was ¥1,372.014 million, down 45.3% year on year, as large-scale replacement projects had run their course by the previous fiscal year and replacement demand was at a trough,」
The completion of large-scale replacement projects and the trough in replacement demand continued, and domestic revenue from blood collection tube preparation equipment and systems fell 45.3% year on year. The timing concentration and volatility risk of equipment sales has become even more evident in actual results. - FY2021-Q2WorsenedAnnual report
「Revenue in the domestic market was ¥810.653 million, down 55.7% year on year, as large-scale replacement projects had run their course by the previous fiscal year and the company entered a fiscal year representing a trough in replacement demand.」
The completion of large-scale replacement projects and the trough in replacement demand continued, and domestic revenue from blood collection tube preparation equipment and systems fell 55.7% year on year. The timing concentration and volatility risk of equipment sales has become further evident in actual results. - FY2021-Q1WorsenedAnnual report
「Revenue in the domestic market was ¥376.706 million, down 56.3% year on year, as large-scale replacement projects had run their course and the fiscal year was one of weak replacement demand,」
The disclosure makes clear that the current fiscal year is a trough in replacement demand following the completion of large-scale replacement projects, with the timing concentration and volatility risk of equipment sales materializing as a decline in domestic sales for the quarter. - FY2019RestatedAnnual report
「Sales of equipment, including our core blood collection tube preparation equipment business, tend to be concentrated in the second half and fourth quarter because of the timing of orders from, and delivery requests by, medical institutions, which are the primary customers for these products.」
The disclosure continues to cover the seasonality of equipment sales, which are concentrated in the second half and fourth quarter, and the risk of fluctuations in the timing of sales recognition caused by delays in introducing higher-level systems. - FY2018RestatedAnnual report
「Sales of equipment, including our core blood collection tube preparation equipment business, tend to be concentrated in the second half and fourth quarter because of the timing of orders from, and delivery requests by, medical institutions, which are the primary customers for these products. If the introduction of the higher-level systems installed by medical institutions to control the blood collection tube preparation equipment is delayed beyond the initially anticipated timing, sales will be recorded in the following fiscal year, potentially causing fluctuations in our results of operations when measured over separately defined periods.」
The disclosure continues to cover the concentration of equipment sales in the second half and fourth quarter and the risk that sales may be deferred to the following fiscal year because of delays in introducing higher-level systems. - FY2017RestatedAnnual report
「Sales of equipment, including our core blood collection tube preparation equipment business, tend to be concentrated in the second half and fourth quarter because of the timing of orders from, and delivery requests by, medical institutions, which are the primary customers for these products.」
The disclosure continues to describe the seasonality of equipment sales, which are concentrated in the second half and fourth quarter, and the risk of performance fluctuations between periods. - FY2016First statedAnnual report
「Sales of equipment, including our core blood collection tube preparation equipment business, tend to be concentrated in the second half and fourth quarter because of the timing of orders from, and delivery requests by, medical institutions, which are the primary customers for these products.」
This indicates that equipment sales may be concentrated in the second half and fourth quarter depending on the timing of orders and delivery requests from medical institutions, potentially causing fluctuations in performance between periods.